Schizophrenia 1 - Clinical (1)

[P132] Interim report of a post-marketing surveillance of paliperidone palmitate 3-month formulation in Japanese patients with schizophrenia.

*Tatsuro Marumoto¹, Yosuke Saga¹, Hiroaki Kinoshita², Natsuko Morita², Tokiko Touma³, Shinya Wakamatsu¹, Kyoko Takebe², Akihide Wakamatsu¹, Chih-Lin Chiang¹ (1. Medical Affairs Division, Janssen Pharmaceutical K.K., 2. Drug Safety Surveillance Department, Japan Safety & Surveillance Division, Janssen Pharmaceutical K.K., 3. Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K.)

Keywords:paliperidone palmitate 3-month formulation, post-marketing surveillance, schizophrenia